Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles: 2010-2024

Historic Amortizatization of Intangibles for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $22,000.

  • Lineage Cell Therapeutics' Amortizatization of Intangibles fell 33.33% to $22,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $119,000, marking a year-over-year decrease of 17.93%. This contributed to the annual value of $22,000 for FY2024, which is 83.08% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Amortizatization of Intangibles stood at $22,000, which was down 83.08% from $130,000 recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Amortizatization of Intangibles ranged from a high of $1.2 million in FY2020 and a low of $22,000 during FY2024.
  • Its 3-year average for Amortizatization of Intangibles is $99,000, with a median of $130,000 in 2023.
  • Data for Lineage Cell Therapeutics' Amortizatization of Intangibles shows a maximum YoY plummeted of 83.08% (in 2024) over the last 5 years.
  • Lineage Cell Therapeutics' Amortizatization of Intangibles (Yearly) stood at $1.2 million in 2020, then crashed by 82.73% to $210,000 in 2021, then slumped by 30.95% to $145,000 in 2022, then decreased by 10.34% to $130,000 in 2023, then crashed by 83.08% to $22,000 in 2024.